Pharma BD Deal Intelligence

Joincare Pharmaceutical Group Industry Co., Ltd. / Brii Biosciences Limited

2025 · Licensing/Option · Complete

Brii Biosciences announced a license and technology transfer agreement with Joincare Pharmaceutical Group on July 3, 2025, granting Joincare an exclusive license to research, develop and commercialize BRII-693 in Greater China. Brii Bio receives an undisclosed upfront payment plus development and commercial milestones and tiered royalties on net product sales, and retains ex-Greater China rights. Financial amounts not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals